Anadys intends to continue testing higher doses of ANA598 in the ongoing phase Ib study while it completes animal toxicity studies the company needs before starting longer combination studies of the drug in hepatitis C patients.
Anadys shares soared Thursday, ending the trading session up 114.7% to $2.19.- Loading Comments...
- Loading Comments...
Featured Photo Galleries
Connect with TheStreet
 |
 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,291.26 | 1,098.51 | 2,166.90 | 34.74 |
Oil *
77.90
|
|
UP
44.29
|
UP
5.50
|
UP
15.82
|
DOWN
0.08
|
10 Yr
3.47%
SPDR Gold
109.60
|
|
+0.43%
|
+0.50%
|
+0.74%
|
-0.23%
|
Data delayed 20 minutes |
